论文部分内容阅读
目的:评价重组人脑利钠肽对失代偿性心力衰竭患者左室射血功能的疗效及其对TNF-α、hs-CRP指标的影响。方法:选取2013年12月—2016年5月间收治的失代偿性心力衰竭患者90例,采用随机分组法将其分为观察组(45例)和对照组(45例);对照组患者给予常规用药治疗,观察组患者在对照组治疗基础上加用重组人脑利钠肽治疗,评价两组患者治疗后的总有效率和治疗前后左心室射血分数(LVEF)及肿瘤坏死因子-α(TNF-α)、高敏C反应蛋白(Hs-CRP)测得值的变化情况。结果:观察组患者治疗后的总有效率为97.78%高于对照组为80.00%(P<0.05);两组患者治疗前后LVEF及TNF-α、Hs-CRP水平,观察组治疗后LVEF值高于对照组(P<0.05),TNF-α和Hs-CRP测得值低于对照组(P<0.05)。结论:采用重组人脑利钠肽治疗失代偿性心力衰竭患者有助于降低TNF-α、Hs-CRP水平,提高了其左室射血功能,疗效较为确切。
Objective: To evaluate the therapeutic effect of recombinant human brain natriuretic peptide on left ventricular ejection function in patients with decompensated heart failure and its effect on the indexes of TNF-α and hs-CRP. Methods: Totally 90 patients with decompensated heart failure who were admitted between December 2013 and May 2016 were randomly divided into observation group (45 cases) and control group (45 cases). Patients in the control group The patients in the observation group were treated with recombinant human brain natriuretic peptide. The total effective rate and the left ventricular ejection fraction (LVEF) and tumor necrosis factor - alpha α (TNF-α), high-sensitivity C-reactive protein (Hs-CRP) measured value changes. Results: The total effective rate of the observation group after treatment was 97.78%, which was significantly higher than that of the control group (80.00%, P <0.05). The levels of LVEF, TNF-α and Hs-CRP in the two groups before and after treatment were significantly higher The levels of TNF-α and Hs-CRP in the control group (P <0.05) were lower than those in the control group (P <0.05). Conclusion: The treatment of patients with decompensated heart failure with recombinant human brain natriuretic peptide is helpful to reduce the levels of TNF-α and Hs-CRP, and improve the left ventricular ejection function.